<bill session="115" type="h" number="1703" updated="2019-04-18T16:05:25Z">
  <state datetime="2017-03-23">REFERRED</state>
  <status>
    <introduced datetime="2017-03-23"/>
  </status>
  <introduced datetime="2017-03-23"/>
  <titles>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act with respect to determining the intended use of drugs and devices.</title>
    <title type="short" as="introduced">Medical Product Communications Act of 2017</title>
    <title type="short" as="introduced">Medical Product Communications Act of 2017</title>
    <title type="display">Medical Product Communications Act of 2017</title>
  </titles>
  <sponsor bioguide_id="G000568"/>
  <cosponsors>
    <cosponsor bioguide_id="B001257" joined="2017-06-02"/>
  </cosponsors>
  <actions>
    <action datetime="2017-03-23">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-03-23" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2017-03-24">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Scientific communication"/>
  </subjects>
  <amendments/>
  <summary date="2017-03-23T04:00:00Z" status="Introduced in House">Medical Product Communications Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to state that the intended use of a drug, biological product, or device shall be determined by the objective intent of the manufacturer and sponsor of such drug, biological product, or device, as demonstrated by statements contained in labeling, advertising, or analogous oral statements.

The intended use of these medical products shall not be determined by actual or constructive knowledge of the manufacturer or sponsor that these products will be used in a manner that varies from the use approved for marketing.

Additionally, the scientific exchange of information about these products shall not constitute labeling, advertising, or evidence of a new intended use.The bill sets forth the requirements for a scientific exchange.</summary>
  <committee-reports/>
</bill>
